Hengrui Pharma continues to implement the development strategy of scientific and technological innovation and internationalization. Focusing on "focusing on innovation and building a multinational pharmaceutical group" has always been Hengrui's vision. Based on the continuous innovation strength, Hengrui Pharma was selected into the list of "Top 50 Innovative Enterprises in China in 2022" published by Forbes China in recent years, and Hengrui Pharma ranked fifth in "Top 50 Innovative Enterprises in China in 2022 100", winning the honor of domestic innovation again.
As a large-scale pharmaceutical company engaged in medical innovation earlier in China, Hengrui Pharma has applied for invention patents 1806, PCT patents 494, domestic effective authorized invention patents 360, and foreign authorized patents 478 in Europe, America and Japan. Is the only pharmaceutical company in China that has entered the global TOP20 biomedical invention patent. I believe that Hengrui Pharma will continue to focus on frontier areas, constantly overcome difficulties and serve a healthy China!